Document ID: chunk:federal_register_of_legislation:F2024L00484:reg:9:p1
Version: federal_register_of_legislation:F2024L00484
Segment Type: reg
Provision Reference: reg 9 (pt 1/2)
Character Range: 4403–8437

9               Factors that must exist
At least one of the following factors must exist before it can be said that, on the balance of probabilities, myasthenia gravis or death from myasthenia gravis is connected with the circumstances of a person's relevant service:
(1)          being treated with one of the following medications within the 3 months before clinical onset:
(a)          alemtuzumab;
(b)          chloroquine;
(c)          etanercept;
(d)          gabapentin;
(e)          HMG coenzyme A reductase inhibitors (statins);
(f)           hydroxychloroquine;
(g)          immune checkpoint inhibitors including ipilimumab, nivolumab, pembrolizumab, atexolizumab, avelumab, dostarlimab, and durvalumab;
(h)          interferon alpha;
(i)            lithium carbonate;
(j)            penicillamine;
(k)          phenytoin;
(l)            trimethadione;
(2)          being treated with one of the following medications at the time of the clinical worsening:
(a)          acetazolamide;
(b)          alemtuzumab
(c)          amantadine;
(d)          amitriptyline;
(e)          anaesthetic agents;
(f)           antibiotics;
(g)          beta-blockers;
(h)          botulinum toxin;
(i)            calcium channel blockers;
(j)            carbamazepine;
(k)          chloroquine;
(l)            chlorpromazine;
(m)        cocaine;
(n)          colchicine;
(o)          diphenhydramine;
(p)          droperidol;
(q)          echothiophate;
(r)           ementine;
(s)           ergometrine;
(t)            etafenone;
(u)          etanercept
(v)          ethosuximide;
(w)        gabapentin;
(x)          haloperidol;
(y)          HMG coenzyme A reductase inhibitors (statins);
(z)          hydroxychloroquine;
(aa)       imipramine;
(bb)      immune checkpoint inhibitors;
(cc)       interferon alpha;
(dd)      interleukin-2;
(ee)       levonorgestrel implant;
(ff)        lithium carbonate;
(gg)      magnesium sulphate;
(hh)      mefloquine;
(ii)         nicotine transdermal patch;
(jj)         paraldehyde;
(kk)      potassium losing diuretics;
(ll)         penicillamine;
(mm) peruvoside;
(nn)      phenytoin;
(oo)      procainamide;
(pp)      proguanil;
(qq)      propafenone;
(rr)        pyrantel pamoate;
(ss)        quinidine;
(tt)         quinine;
(uu)      ribavirin;
(vv)      sedative analgesics including barbiturates, muscle relaxants, narcotics and tranquillisers;
(ww)  systemic corticosteroids;
(xx)      thyroid hormone replacement therapy;
(yy)      tiopronin;
(zz)       trientine;
(aaa)   trihexyphenidyl;
(bbb)  trimethadione;
(ccc)   trimethaphan;
(3)          having an injection of an iodinated radiological contrast agent within the 24 hours before clinical worsening;
Note: Iodinated contrast agents include but are not limited to iothalamic acid, diatrizoate meglumine and diatrizoate sodium.
(4)          undergoing haematopoietic stem cell transplantation before clinical onset or clinical worsening;
(5)          being pregnant within the 6 weeks before clinical worsening;
(6)          having an infection with any of the following conditions in the 2 months before clinical worsening:
(a)          pneumonia;
(b)          influenza;
(c)          severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection;
(d)          upper respiratory tract infection;
(e)          urinary tract infection;
(f)           gastrointestinal infection;
(g)          septicaemia;
(7)          having major surgery or major trauma within the 2 months before clinical worsening;
(8)          receiving the ChAdOx1 nCoV-19 vaccine within the 2 months before  clinical onset or clinical worsening;
(9)          experiencing a category 1A stressor within the 2 weeks before clinical worsening;
Note: category 1A stressor is defined in the Schedule 1 – Dictionary.
(10)      experiencing a category 1B stressor within the 2 weeks before clinical worsening;
Note: category 1B stressor is defined in the Schedule 1 – Dictionary.
(11)      experiencing a category 2 stressor within the 1 year before clinical